Dungubat, Erdenetsogt
Loading...
Товч нэр
Dungubat, Erdenetsogt
Бүтэн нэр
Dungubat Erdenetsogt
Латин нэр
Dungubat Erdenetsogt
Албан тушаал
Судлаач
18 results
Now showing 1 - 10 of 18
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Anti-HCV, HBsAg Positive Incidences Among Patients Aged 40 Years and Over Diagnosed with B- Non-Hodgkin’s Lymphoma: A Comparison with General Population of Same Age(Mongolian National University of Medical Sciences, 2019-12-29); ;Delgerbat Boldbaatar ;Anir Enkhbat; Khishigjargal BatsukhObjectives: There are several risk factors contribute to the development of the B-cell Non-Hodgkin’s lymphoma (B-NHL) among which hepatitis B, hepatitis C virus (HBV, HCV) infection, as well as old age, are known to have a signi cant effect. Previous studies examining the relationship between HBV, HCV infection and B-NHL show inconsistent results in different endemic areas. Methods: We compared the hepatitis B surface antigen (HBsAg) and antibody against the HCV (anti-HCV) positive incidences among aged 40 years or older patients who have been newly diagnosed with B-NHL, between 2015 and 2018, to prevalence of hepatitis B and C virus infection in the general population of Mongolia in the same age by data of the general population in hepatitis screening and the results of previous studies on the Mongolian population. Results: A total of 187 patients, newly diagnosed with B-NHL ≥40years of age took part in our study. In case of these two groups, the prevalence of HBsAg in the B-NHL population was close to the general population while anti-HCV positive was signi cantly higher in the B-NHL group (p<.00001). Conclusion: Further studies are needed to clarify the reasons and contributing factors which result situations where the HBV prevalence among B-NHL patients and the general population are not signi cantly different. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Determination of Filaggrin Gene Single Nucleotides Polymorphisms in Patients with Atopic Dermatitis(Mongolian National University of Medical Sciences, 2017-02-25); ; ;Ariunaa Munkhbayar; Objectives: The protein, filaggrin, is important in barrier function and epidermal differentiation facilitation. Filaggrin gene (FLG) mutations have been identified as the cause of ichthyosis vulgaris (IV), and certain mutations have been associated with atopic dermatitis (AD). We aimed to investigate genetic polymorphism of FLG in Mongolian AD patients. Methods: FLG mutations were determined using sequence analysis in 46 AD patients and 12 IV patients. Severity of AD was assessed using the Scoring Atopic Dermatitis (SCORAD) index. Allergen specific IgE were determined from serum. Filaggrin expression in skin punch biopsy samples of AD patients was investigated using immunohistochemistry (IHC). Results: Several single nucleotides polymorphisms (SNPs) (1150C>T, 1741A>T, 1791C>T, 2181C>G, 2191A>G, and 2263G>A) were demonstrated in AD patients using sequence analysis. Total IgE levels were significantly associated with age (p=0.03) and duration of disease (p=0.02). Presence of SNPs and mixed allergen specific IgE was significantly correlated (p=0.02); 2 SNPs were significantly associated with food allergen specific IgE levels (p=0.009). 2263G>A SNP was significantly correlated with food allergen specific IgE (p=0.003) and a history of atopic diseases (p=0.03). Conclusion: New mutations or genetic polymorphisms with ethnic characteristics may be detected among Mongolians. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Impact of Hepatitis D Coinfection on the Hepatitis Flare during Chemotherapy for B-Cell Non-Hodgkin Lymphoma(Mongolian National University of Medical Sciences, 2020-04-01); ;Anir Enkhbat ;Delgerbat Boldbaatar ;Khishigjargal BatsukhAltankhuu MurdojObjectives: This study was conducted to determine the effect of Hepatitis B infection with or without D coinfection on the hepatitis flare associated with chemotherapy for B-Cell non-Hodgkin lymphoma. Methods: The hepatitis flare related to the chemotherapy for newly diagnosed B-Cell non-Hodgkin lymphoma was studied in HBV mono-infected and HBV and HDV coinfected patients between 2015 and 2018. Results: Nineteen HBsAg positive patients satisfied the inclusion criteria. In the group with the hepatitis flare, 14.3% were anti-HDV negative and 83.3% were anti-HDV positive (p<.006). Also, the hepatitis flare occurred in all patients where HDV-RNA was detected, while it had occurred in 60% of patients where HDV-RNA was not detected. Conclusion: The hepatitis flare related to chemotherapy occurred more frequently in B-Cell non-Hodgkin lymphoma patients coinfected with HBV and HDV without antiviral prophylaxis, especially when HDV-RNA was detected. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Hepatitis C Associated B-Cell Non-Hodgkin Lymphoma: Impact of Combination Direct-Acting Antivirals and Chemotherapy(Mongolian National University of Medical Sciences, 2021-12-31); ;Delgerbat Boldbaatar ;Khishigjargal Batsukh; Objectives: Direct-acting antiviral agents (DAAs) have successfully eradicated chronic hepatitis C virus (HCV) infection. Since chronic HCV is known to have an increased risk of developing B cell non-Hodgkin lymphoma (B-NHL), successful HCV treatment may have virologic, hepatic, and oncologic benefits for B-NHL. Therefore, this study aimed to determine the efficacy of DAAs combined with chemotherapy in B-NHL patients with chronic HCV in Mongolia. Methods: This case-control study included newly diagnosed B-NHL patients with chronic HCV who received DAAs before chemotherapy (with DAAs group). The other is comprised of controls who have been treated by chemotherapy without DAAs. Patients who received courses of DAAs were monitored by the virological and hepatic responses. Results: Eleven patients received DAAs and none of them developed chemotherapy-associated hepatitis flare. Of the DAAs group, during DAAs treatment, 90.9% were clinically stable. In all cases of DAAs in combination with chemotherapy, the Sustained Viral Response (SVR)12 and 24 were 100%. However, 47.4% of those who received DAAs after chemotherapy developed hepatitis flare during chemotherapy. Patients with hepatitis flare had higher serum level of ALT before chemotherapy (15.7 U/L vs. 40.2 U/L; p = 0.014) than those without. Conclusion: DAAs administration results in a significant clinical benefit to B-NHL patients with chronic HCV. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Morphometric study of facial wrinkles and aesthetic skin as dermaroller treatment combined with platelet rich plasma (PRP)(2017-01-02); ; ; Abstract Background: Facial wrinkles are a multifactorial, complex process that negatively affects individuals’ appearance, consequently their quality of life. The treatment for these wrinkles varies with the degree of severity. This prospective study aimed to evaluate the clinical effect of pure dermaroller and dermaroller combined with platelet rich plasma therapy (PRP dermaroller), to treat facial wrinkles, and to quantitatively evaluate histological changes of the skin that occur in the two different cohorts. Methods and materials: Twenty healthy women aged 43-48 years with scores ranging between 2 and 4 on the baseline facial fine wrinkle grading scale were enrolled in the this clinical study. Nineteen of the patients were treated with a pure dermaroller on the one half of face, and with a dermaroller that included a platelet rich plasma on the other half of the face. Three treatments, each in a 4 weeks interval were performed. Standard photographs and skin biopsies were obtained from the treatment area at baseline and 8 weeks after the final session. Comparisons of the treatments were analyzed using clinical and histological findings. Results: The degree of baseline facial fine wrinkle grading scale after treatment revealed statistically significant effects of the PRP dermaroller treatment side compared to the side of pure dermaroller treatment. At 8 weeks after the final session, the wrinkling grade on the PRP dermaroller side and the pure dermaroller side showed significant differences (p<0.05). Microscopic evaluation of haematoxylin eosin and Masson’s trichrome stained sections revealed significant differences in dermal fibers, epidermal thickness, papillas and skin glands. Conclusion: Significant changes were noted between treatments of facial wrinkles with pure dermaroller and PRP dermaroller. Dermaroller combined with platelet rich plasma is a promising novel method of facial rejuvenation. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Functional Abnormalities of the Liver in Diabetic Patients with and without Hepatitis C(Mongolian National University of Medical Sciences, 2019-03-31); ; ; ; Objective: We aimed to compare liver function of diabetes mellitus patients with and without viral hepatitis C using the non-alcoholic fatty liver disease fibrosis score, aspartate transaminase to platelet ratio index, Fibrosis-4 Index, Mac-2-binding protein biomarker and ultrasonic liver stiffness measurements. Methods: The study was conducted based on convenience sampling of 123 patients. Slightly more than half of the study participants were male (53%, n=64). Thirty-three of the diabetics with hepatitis (mean age 52.31±9.8 years) and 90 diabetics without hepatitis (mean age 53.26±8.58) agreed to participate. Anthropometric measurements, non-alcoholic fatty liver disease fibrosis score, aspartate transaminase to platelet ratio index, Fibrosis-4 Index, Mac-2-binding protein biomarker, and ultrasonic transient elastography measurements were compared using independent t-tests for continuous variables and Wilcoxon rank sum tests for ordinal variables. Results: The median values of the Fibrosis-4 Index for those with and without hepatitis C were 1.3 vs. 0.9 (p<.05), Mac-2-binding protein biomarker 2.0 vs. 1.3 (p<.0001), ultrasonic liver stiffness measurements 10.3 vs. 6.9 (p<.0001), aspartate transaminase to platelet ratio 0.6 vs. 0.3 (p<.001), and Non-alcoholic fatty liver disease fibrosis scores were -0.2 vs. -0.9 ( p<.004), respectively Conclusions: Diabetic patients with hepatitis had statistically significantly higher Mac-2-binding protein biomarker, NAFLD Fibrosis Scores than patients without hepatitis. However, other fibrosis test results were similar in diabetic patients with hepatitis and without hepatitis C. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Randomized Controlled Trial Comparing Standard Triple and Sequential Regimens for Helicobacter pylori Eradication(Mongolian National University of Medical Sciences, 2016-11-25); ; ; ; Objectives: The aim of this study was to compare effectiveness of sequential therapy to the standard triple therapy to eradicate Helicobacter pylori (H. pylori) in Mongolia. Methods: From September 2014 to February 2016, 140 patients with confirmed H. pylori infection (upper gastrointestinal tract (GI) endoscopy, rapid urease test, histology, H. pylori stool antigen test (HpStAg)) randomly received 10 days standard triple therapy (20 mg pantoprazole, 1 g amoxicillin, 500 mg clarithromycin, all twice daily for 10 days; STT group, n = 70), and sequential therapy (20 mg pantoprazole, 1 g amoxicillin twice daily for 5 days followed by 20 mg pantoprazole, 500 mg clarithromycin, 500 mg metronidazole twice daily for 5 days; SQT group, n = 70). Successful eradication therapy for H. pylori infection was defined as a negative HpStAg test 4 weeks after the end of eradication treatment. Results: The eradication rates by intention to treat (ITT) analysis were 71.4% (50/70) and 50% (35/70) in the STT and SQT groups, respectively (p = 0.033). The eradication rates by per-protocol (PP) analysis were 72.5% (50/69) and 51.5% (35/68) in the STT and SQT groups, respectively (p = 0.018). The adverse event rates were 7.6% (5/70) and 18.6% (13/70) in the STT and SQT groups, respectively (p = 0.043). Conclusion: The eradication rate was significantly higher in the STT group compared with the SQT group. But the eradication efficacies of both STT and SQT for H. pylori infection in Mongolia are unacceptable. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Measurement of Liver Fibrosis in Chronic Hepatitis D: Comparison of Invasive and Non-Invasive Methods(Mongolian National University of Medical Sciences, 2019-03-31); ;Dorj, Sumiya ;Jamsranjav, Selenge; Objectives: The aim of this study was to compare non-invasive methods in the detection of hepatic fibrosis in patients with chronic hepatitis delta. Methods: Twelve patients with chronic hepatitis delta who visited the Gastroenterology Department at the Intermed Hospital, were studied. Clinical and histological data were evaluated and serum indirect fibrosis markers including AST to ALT ratio, AST-to-Platelet Ratio, Fibrosis-4 index scores were calculated. Serum Mac-2 binding protein glycosylation isomer and liver stiffness measurements were performed in all participants. Results: Histological scoring showed that 16.7%, 41.7% and 41.7% of participants had F2, F3, and F4 stage of liver fibrosis, respectively. All participants were divided into groups; cirrhotic (F4) and non-cirrhotic (F0-F3). The median AST to ALT ratio in cirrhotic vs. noncirrhotic patients was 1.4 vs. 1.1 (p=.67), AST-to-Platelet ratios were 0.7 vs. 1.1 (p=.48), and Fibrosis-4 index scores were 1.8 vs. 1.6 (p=.82) in non-cirrhotic patients. Median Mac-2 binding protein glycosylation isomer levels in the cirrhotic group 1.3 cut-off index vs. 1.4 cut-off index in the non-cirrhotic group (p=.85). The median liver stiffness was 12.6 kPa in cirrhotic patients while 8.1 kPa in non-cirrhotic patients (p=.05). Conclusion: Non-invasive serum markers were less accurate in determining fibrosis in chronic hepatitis delta patients. Liver stiffness measurement was superior to the non-invasive serum markers. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Helicobacter pylori-ийн халдварын дахилт, түүнд нөлөөлөх зарим эрсдэлт хүчин зүйлс(2021-09-01) ;Б.Сувданцэцэг; ; ;Д.СоёлмааА.ТуяаҮндэслэл: Helicobacter pylori (H.pylori)-ийн халдварын дахилт жил тутам хөгжингүй орнуудад 2.7%, хөгжиж буй орнуудад 13% байгаа бөгөөд Монгол улсын хэмжээнд одоогоор энэ чиглэлээр хийгдсэн судалгаа байхгүй байна. Зорилго, зорилт: H.pylori-ийг устгах эмчилгээний дараах халдварын дахилт, түүнд нөлөөлөх зарим эрсдэлт хүчин зүйлсийг тодорхойлох Материал ба арга зүй: Судалгааг проспектив когорт судалгааны загвараар АШУҮИС, Их сургуулийн нэгдсэн эмнэлэг (ИСНЭ),Төрийн тусгай албан хаагчдын нэгдсэн эмнэлэг (ТТАХНЭ)-т тус тус явуулсан. 2014 оны 03 сараас 2021 оны 03 сарын хооронд H.pylori-ийг устгах эмчилгээ хийлгэж H.pylori устсан хүмүүсийг уг судалгаанд хамруулсан. Судалгааны явцад буюу 1-7 жилийн хугацаанд жил тутам H.pylori-ийг илрүүлэх шинжилгээнд хамруулан, 2 ба түүнээс дээш шинжилгээнд H.pylori эерэг гарсан тохиолдолд H.pylori-ийн халдварын дахилт гэж үнэлэв. H.pylori-ийн халдварын дахилт эмчилгээний дараах 12 сараас дээш хугацаанд тодорхойлогдвол дахин халдвар гэж үнэлсэн. Дахин халдварт нөлөөлөх эрсдэлт хүчин зүйлийг олон хүчин зүйлийн кокс регрессийн аргаар хийж, эрсдэлт хүчин зүйлсийн дан ба хавсарсан нөлөөллийг үнэлж, харьцуулсан харьцаа (HR), түүний 95% итгэх интервал статистик үнэн магадлал тооцсон. Үр дүн: Судалгаанд нийт 204 хүн хамрагдсанаас хяналтын 6-84 сарын хугацаанд нийт оролцогчдын 62.7% нь хамрагдсан. Эмчилгээний дараах 6-12 сарын хугацаанд 128 хүн шинжилгээнд хамрагдаж 15 буюу 11.7% (128/15)-д нь H.pylori-ийн халдварын сэдрэлт илэрсэн. Эмчилгээний дараах нийт 6 жилийн хугацаанд дахин халдвар 29.1% (58/199), дунджаар 1 жилд 4.85%-тай байна. Судалгааны явцад буюу нийт 7 жилийн хугацаанд H.pylori халдварын дахилт 22.3% (73/327), үүний 20% нь сэдрэлт, 80% нь дахин халдвар байдлаар тохиолдож байна. H.pylori-ийн дахин халдварт олон нийтийн газарт хооллох (HR=2.1, 95%CI: 1.23-3.86), гэр бүлийн гишүүдийн тоо олон байх (HR=2.4, 95%CI: 1.354.34), гэр бүлийн гишүүд зэрэг эмчлүүлээгүй байх (HR=1.9, 95%CI: 1.01-3.69), гэр бүлийн гишүүд ходоодны хавдрын өгүүлэмжтэй байх (HR=2.57, 95%CI: 1.51-4.41) зөөврийн ус хэрэглэдэг байх (HR=1.4, 95%CI: 1.03-2.11) (бүгд p<0.05) зэрэг нь нөлөөлөх эрсдэлт хүчин зүйл болж байна. Дүгнэлт: Монгол улсад H.pylori-ийн халдварын дахилт харьцангуй өндөр байна. Олон нийтийн газарт хооллох давтамжийг бууруулж, H.pylori устгах эмчилгээг гэр бүлийн гишүүн бүрт зэрэг хийлгэснээр H.pylori-ийн халдварын дахилтыг бууруулах боломжтой байна. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, В эсийн Ходжкины бус лимфома оношлогдсон эмчлүүлэгчдэд вирүсийн эсрэг эмчилгээний зарим үр дүн(2021-03-21); ;Б.Хишигжаргал ;Б.Дэлгэрбат ;Б.ЭнхтуулСүүлийн 15-20 жилд хийгдсэн эпидемиологи, молекул биологи, вирүсийн эсрэг эмчилгээ зэрэг олон төрөл судалгааг үндэслээд хепатитын С вирүс (ХСВ) болон В эсийн Ходжкины бус лимфома (В-ХБЛ) хоорондын холбоо, хамаарлыг нийтээр хүлээн зөвшөөрч байна.1,2 ХСВ-ийн халдвар нутагшмал Монголчуудад ХСВ-ийн архаг халдвар бүхий В-ХБЛ-той эмчлүүлэгчдэд ВЭШҮ эмийн эмчилгээ хэрхэн нөлөөлөхийг судлах нь практикийн чухал ач холбогдолтой юм. Шинээр В-ХБЛ оношлогдсон, ХСВ-ийн архаг халдвартай эмчлүүлэгчдээс ВЭШҮ эмийн эмчилгээ хийгээд хими эмчилгээнд орсон ба шууд хими эмчилгээнд орсон 2 бүлгийг хими эмчилгээний үе (хими эмчилгээний эхний циклээс хойш 10 хоногийн дараагаас сүүлийн цикл хими эмчилгээнээс <30 хоног хүртлэх хугацааны)-ийн эмнэлзүй ба шинжилгээний үзүүлэлтээр харьцуулан дагаж судалсан. Шинээр В-ХБЛ-оношлогдсон, ХСВ-ийн архаг халдвартай 11 (6 эмэгтэй, 5 эрэгтэй) хүн (бүгд ХСВ-ийн омог 1b байсан ба Sofosbuvir Ledipasvir эм уусан) ВЭШҮ эмийн эмчилгээ бүрэн хийгдэж дуусгасан байна. Дүгнэлт: 1. Шинэ оношлогдсон В-ХБЛ-ын ХСВ-ийн архаг халдвар хавсарсан эмчлүүлэгчдэд хими эмчилгээний өмнө, хими эмчилгээтэй нь хавсруулан, хими эмчилгээний дараа ВЭШҮ эмийн эмчилгээг хийхэд В-ХБЛ-ын эмнэлзүйн талаас хүндрэл гараагүй ба аль ч тохиолдолд ХСВ бүрэн эдгэрсэн буюу вирүсийн тогтвортой хариу илэрсэн болно. 2. ХСВ-ийн архаг халдвар хавсарсан В-ХБЛ-ын үед ВЭШҮ эмийн эмчилгээг хими эмчилгээний өмнө ба хавсран хийх нь төлөвлөсөн хими эмчилгээг гүйцэт хийх боломжийг нэмэгдүүлж байна.
